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Background: Previous research suggests a link between antidepressant use anddiabetes, but it is unclearwhether the association is causal
or attributable to detection/ascertainment bias. To examine this, we assessed the associations of antidepressant usewith change in glucose
levels and incidence of undiagnosed and diagnosed diabetes.
Methods: During an 18-year period, we monitored antidepressant use, glucose levels, and diabetes status in 5978 civil servants (70.9%
male, age range 39–64 years) free of diabetes at baseline (the Whitehall II study). Use of medication and plasma glucose were assessed at
four study screenings: 1991/1993, 1997/1999, 2003/2004, and 2008/2009. Incident diabetes cases were classified as either diagnosed (n
94) if detected using self-report of physician diagnosis and/or the use of diabetes medication or undiagnosed (n 346) if detected based
n fasting and/or 2-hour postload glucose levels using an oral glucose tolerance test at the study screenings.
esults: Incidence of diagnosed diabeteswas higher among antidepressant users than nonusers (odds ratio 3.10, 95% confidence interval:
.66–5.78). However, antidepressant use was not associated with undiagnosed diabetes at any follow-up examination nor with higher
asting or 2-hour postload plasma glucose levels or increasing glucose levels over time. Odds ratio for undiagnosed diabetes for antidepres-
ant users versus nonusers was .88 (95% confidence interval: .45–1.72, p  .70). The mean difference in glucose changes between
participants reporting antidepressant use at three screenings compared with those not on antidepressant treatment was .0 mmol/L.
Conclusions: The link between antidepressant use and diabetes risk may not be causal in nature.t
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A ntidepressants are among themost prescribeddrugsworld-wide (1,2). Recent large-scale studies based on medical re-cords have linked antidepressant medication use with type
diabetes, raising the concern that persistent use of antidepres-
ants might increase the risk of diabetes (3–10). However, these
ndings should be interpreted with caution. First, the association
ay be due to indication bias (11); that is, the true association may
ot be between themedication and the outcome but between the
ndication for the medication and the outcome, in this case be-
ween depression and incidence of diabetes. Second, detection/
scertainment bias is possible as depressed patients on antidepres-
ant treatment may use health services more often than untreated
atients or nondepressed people, increasing their likelihood of be-
ng diagnosedwithmedical conditions such as diabetes (12). Third,
he relation between depression and diabetes is complex, poten-
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doi:10.1016/j.biopsych.2011.07.008ially bidirectional, and it is also likely to reflect commonantecedent
auses, such as obesity, socioeconomic status, and lifestyle factors
13–15). Thismay confoundobserved associationsbetweenantide-
ressant use and diabetes.
In the present study, we used data from the British Whitehall II
ongitudinal study to evaluate the relation between antidepressant
se and diabetes. We examined the strength of this association in
hysician-diagnosed diabetes (diagnosis made by health care pro-
ider before the Whitehall II study screening) as compared with
tudy screen-detecteddiabetes (diabetes detected for the first time
y routine blood testing as part of the Whitehall II study). Crucially,
obust and equally strong associations with physician-diagnosed
nd screen-detected diabetes would provide evidence against de-
ection/ascertainment bias. We also examined the association be-
ween antidepressant medication use and subsequent change in
lood glucose levels in nondiabetic persons. If antidepressant use
ncreases diabetes risk, then nondiabetic antidepressant users
ould show greater increases in fasting and/or postload glucose
oncentrations compared with nonusers.
ethods andMaterials
tudy Population
We used data from the British Whitehall II study of 10,308 civil
ervants aged35 to 55 years at recruitment in 1985/1988 (16). In the
991/1993 sweep of data collection (phase 3), participants under-
ent an oral glucose tolerance test (OGTT) for the first time. This
hase forms the baseline for the analyses we report here. Clinical
xamination with OGTT was repeated on three subsequent occa-
ions, in 1997/1999 (phase 5), 2003/2004 (phase 7), and 2008/2009
phase 9) (17). A total of 5978men and womenwithout diabetes at
aseline participated at least in one of the three follow-up exami-
ations and formed theanalytic sampleof thepresent study (Figure
BIOL PSYCHIATRY 2011;70:978–984
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M. Kivima¨ki et al. BIOL PSYCHIATRY 2011;70:978–984 9791). The University College London ethics committee reviewed and
approved the study; written informed consent was obtained from
each participant at each clinical examination.
Assessment of Clinical Characteristics
Demographic characteristics at each examinationwere age, sex,
ethnicity (White vs. non-White), and socioeconomic status, defined
by the current or most recent employment grade in the British civil
service, divided into three categories (high  administrative; me-
dium professional or executive, and low clerical or support).
At each clinical examination, body mass index (weight [kg]/
height squared [m2]), waist circumference, and systolic blood pres-
sure were measured using standardized protocols (18,19). On the
fasting samples, lipid profile, including assessments of high-density
lipoprotein cholesterol and triglycerides, were analyzed as previ-
ously described (20). Use of antihypertensive and lipid-lowering
medication and smoking status (current smoker vs. nonsmoker)
were requested. Physical activity was assessed based on response
to questions on the frequency and duration of participation in
moderately energetic (e.g., dancing, cycling), and vigorous physical
activity (e.g., running, playing squash). Participants were classified
as inactive (1 hour/week of moderate physical activity and 1
hour/week of vigorous physical activity) versus other. Alcohol con-
sumption in the previous week was measured as units per week.
Severity of depressive symptoms, assessed only in 2003/2004, was
defined based on the summary score of the Center for Epidemio-
logic Studies Depression Scale (21), a measure that has been vali-
dated among diabetic patients (22).
Assessment of Antidepressant Medication Use and Type 2
Diabetes
At each screening, participants provided details of currentmed-
ications use (generic name, brand name, or both); these were sub-
sequently coded using the British National Formulary to determine
antidepressant use (23). At each screening, blood was drawn after
Figure 1. Study flow diagram for diabetes analyses.at least 5 hours of fasting. An OGTT involved studymembers drink- ang a 75 g glucose solution, 2 hours after which venous blood was
gain taken. Blood glucose was measured using the glucose oxi-
ase method (24) on a YSI MODEL 2300 STAT PLUS Analyzer (YSI
orporation, Yellow Springs, Ohio) (mean coefficient of variation:
.4%–3.1%) (25). Type 2 diabetes was defined as fasting glucose
7.0 mmol/L or a 2-hour postload glucose 11.1 mmol/L during
he OGTT performed at the Whitehall screening and as physician-
iagnosed diabetes or use of diabetes medication for those with
iagnosed diabetes (26). At each screening, diabetes cases were
lassified as physician-diagnosed if their clinical diagnosis was al-
eady known (i.e., they reported that their family physician had
iagnosed diabetes and/or prescribed antidiabetic medication) or
s study screen-detected if their diagnosis was firstmade by abnor-
al fasting or 2-hour postloadglucose levels during theWhitehall II
linical screening.
In the Whitehall II results letter sent to all study participants, we
eported abnormal results (including raised glucose) and advised
heparticipants to contact their general practitioner, butweneither
creened for clinical depression nor assessed the need for antide-
ressant therapy.
tatistical Analysis
All statistical analyses were performed using STATA 11.0 soft-
are (StataCorp LP, College Station, Texas). Statistical tests were
wo-sided; a p value of less than .05 was considered statistically
ignificant. Differences in baseline characteristics between study
articipants treated with antidepressants at any of the four clinical
creenings and those never on antidepressants (irrespective of dia-
etes during the follow-up) were tested by using chi-square test
nd analysis of variance, as appropriate.
In all analyses, diabetes (irrespective of physician-diagnosed or
creen-detected) was considered only at the first occurrence and
oded as missing value at subsequent phases. We used logistic
egression analysis to examine the age-, sex-, and ethnicity-ad-
usted associations of antidepressant use at baseline (phase 3) with
ncident physician-diagnosed diabetes and incident study screen-
etected diabetes at any of the phases 5, 7, or 9. To obtain an
stimate of the cross-sectional associations between time-depen-
ent measures of antidepressant use and incident physician-diag-
osed and study screen-detected diabetes at phases 5, 7, and 9, we
sed multilevel logistic regression with the generalized estimating
quations method (Supplement 1 gives details for this method).
To examine biological plausibility (i.e., the association between
ntidepressant use and change in glucose levels), we plotted unad-
usted means of fasting and 2-hour plasma glucose at each study
hase by status of antidepressant use and fitted age-, sex-, and
thnicity-adjusted linear trends in glucose levels across the study
hases among participants not diagnosed as diabetic by a physi-
ian (trends were obtained using multilevel linear regression with
articipant as the clustering factor and study phase as the time
ariable). We used linear regression to determine whether antide-
ressant use at each clinical screening predicted subsequent
hange in fasting and 2-hour plasma glucose levels between that
nd the following examination. We performed multilevel linear
egression analyses, with generalized estimating equations, to ob-
ain a combined estimate for these associations across the phases
i.e., antidepressant use at phase 3 predicting change in glucose
etween phases 3 and 5, antidepressant use at phase 5 predicting
lucose change between phases 5 and 7, and antidepressant use at
hase 7 predicting change in glucose between phases 7 and 9)
Supplement 1 gives details for this method). We ran a correspond-
ng analysis for the association between length of exposure to
ntidepressant use (defined as the number of times reported anti-
www.sobp.org/journal
t
(
a
p
p
e
w
D
o
p
w
b
d
3
s
f
f
C
004),
6 at p
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and subsequent change in glucose levels (see Supplement 1 for
details).
To examine potential confounding, we repeated the analyses
withmultiple clinical characteristics at each phase added as covari-
ates in the model. As a test of reverse causation, we performed a
logistic regression on diabetes status at baseline as a predictor of
antidepressant use at follow-up among participants not on antide-
pressant treatment at baseline.
Results
Of the5978participants, 70.9% (n4238)weremen, 92.0% (n
5501) wereWhite, and 1.6% (n 94) were treated with antidepres-
sants at study baseline. Mean age at baseline was 49.2 (range 39–
64) years. These figures were very similar among all 6924 nondia-
betic participants at baseline (70.0% male, 91.4% White, mean age
49.3 years, prevalence of antidepressant users 1.7%), as well as
among all 7174 successfully screened participants (69.9% male,
90.7% White, mean age 49.4 years, prevalence of antidepressant
users 1.7%) (Figure 1).
Table 1. Baseline Characteristics of the Study Population by Antidepressan
Baseline Characteristica
Never Usersb
Number of
Participants Me
Mean Age, Years 5559 4
Sex, % Male 5559 7
Ethnicity, % White 5559 9
Occupational Position, % High 5524 4
Body Mass Index, kg/m2 5524 2
Waist Circumference, cm 5462 8
Systolic Blood Pressure, mm Hg 5527
HDL Cholesterol, mmol/L 5515
Triglycerides, mmol/L 5532
Antihypertensive Medication, % 5559
Lipid-Lowering Medication, % 5559
urrent Smoking, % 5524 1
Alcohol Consumption, Units per Week 5520 1
Sedentary Lifestyle, % 5526 1
Depressive Symptoms, % c 4503 1
HDL, high-density lipoprotein; SD, standard deviation.
a Baseline refers to phase 3 (1991/1993) in the Whitehall II study. The nu
b Antidepressant use was assessed at phases 3, 5 (1997/1999), 7 (2003/2
c Based on Center for Epidemiologic Studies Depression Scale score1
Table 2. Status of Antidepressant Use at Baseline an
Detectiona
Number of Participants
(Number of Diabetes
Cases)
Antidepressant Use
at Phase 3
No 5884 (282)
Yes 94 (12)
Antidepressant Use
at Phase 3
No 5884 (340)
Yes 94 (6)
a Baseline refers to phase 3 (1991/1993) in theWh
7 (2003/2004), and 9 (2008/2009). All participants were fr
diabetes are adjusted for age, sex, and ethnicity.
www.sobp.org/journalTable 1 shows baseline characteristics for study participants
reated with antidepressants at any of the four clinical screenings
7.0%, n 419) as compared with those not on antidepressants. In
ddition to depressive symptoms (measured at phase 7), antide-
ressant use was associated with female sex, lower occupational
osition, more frequent antihypertensive medication use and sed-
ntary lifestyle, higher prevalence of smoking, and slightly smaller
aist circumference.
iabetes Risk
We identified 346 study screen-detected diabetes cases in one
f the three follow-up screenings; 294 were diagnosed by their
hysician before the screening. Use of antidepressants at baseline
as not associated with incident study screen-detected diabetes
ut a strong association was observed with incident physician-
iagnosed diabetes (age-, sex-, and ethnicity-adjusted odds ratio
.10, 95% confidence interval [CI]: 1.66, 5.78; Table 2). There was no
tatistical evidence of sex differences in these associations (p values
or sex interaction .22 and .80 in models containing the main ef-
ects).
ication Use, the Whitehall II Study (n 5978)
Ever Usersb
p Value) or %
Number of
Participants Mean (SD) or %
.0) 419 48.9 (5.8) .24
419 58.2 .0001
419 94.5 .051
419 32.5 .001
.5) 418 25.1 (3.8) .96
1.3) 414 84.2 (12.7) .01
13) 419 119 (13) .06
4) 418 1.5 (.4) .11
.1) 419 1.4 (1.0) .53
419 8.6 .006
419 .1 .49
419 16.0 .01
2.6) 418 10.1 (12.9) .39
419 26.5 .0001
340 37.7 .0001
s in characteristic slightly vary due to missing values.
and 9 (2008/2009).
hase 7.
ident Diabetes Mellitus at Follow-up by Method of
ds Ratio 95% Confidence Interval p Value
utcome: Incident physician-diagnosed diabetes
1.00
3.10 (1.66 to 5.78) .0001
utcome: Incident study screen-detected diabetes
1.00
1.24 (.54 to 2.87) .62
ll II study. Follow-up refers to phases 5 (1997/1999),t Med
an (SD
9.2 (6
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M. Kivima¨ki et al. BIOL PSYCHIATRY 2011;70:978–984 981Table 3 shows cross-sectional associations between antidepres-
sant use and incident diabetes over the repeated measurements.
Again, no association with study screen-detected diabetes (ad-
justed odds ratio across phases 5, 7, and 9: .88, 95%CI: .45, 1.72) and
a strong association with physician-diagnosed diabetes (odds ratio
2.34, 95% CI: 1.46, 3.75) were observed (for phase-specific associa-
tions, see Table S1 in Supplement 1).
Change in Plasma Glucose Levels
In further analyses, participants with physician-diagnosed dia-
betes at any screening were excluded from the analysis. Data for
fasting and 2-hour plasma glucose levels were available for 5487
and 4991 participants, respectively. As shown in Figure 2, unad-
justedmeanplasmaglucose levels at each studyphasewere similar
for antidepressant users and nonusers. In addition, no difference
was seen in age-, sex-, and ethnicity-adjusted trends over time in
fasting glucose (p values for antidepressant and antidepressant
time interaction terms .26 and .11, respectively) or 2-hour postload
Table 3. Cross-Sectional Association Between Statu
Method of Detectiona
Phase
Antidepressant
Use
Number of Observations
(Number of Diabetes Cases)
Phases 5 to 9
Combined
No 19,767 (274)b
Yes 569 (20)b
Phases 3 to 9
Combined
No 20,060 (337)b
Yes 569 (9)b
a Odds ratios are from age-, sex-, and ethnicity
observations over study phases with generalized e
occurrence and coded as missing value at subseque
b The analysis is based on 5978 participants, of w
346 incident screen-detected diabetes.
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Figure 2.Mean fasting plasma glucose (A) (n 5487) and 2-hour postloads
plasma glucose (B) (n  4991) by study phase and antidepressant use.
Linear trends are adjusted for age, sex, and ethnicity.lucose (p values .37 and .32) between thegroups. A corresponding
ithin-person change analysis fitted with fixed-effect estimator
eplicated this finding (p values .12 and .18 for fasting glucose and
77 and .76 for postload glucose).
Similarly, neither status of antidepressant use nor length of ex-
osure to antidepressant use was associated with subsequent
hange in fasting or 2-hour glucose (Table 4; for phase-specific
nalysis, see Table S2 in Supplement 1). For example, the mean
ifference in fastingand2-hourpostloadglucose changesbetween
articipants reporting antidepressant use at three examinations
ompared with those not on antidepressants was .0 mmol/L.
nalysis of Confounding and Reverse Causation
The association between antidepressant use and physician-di-
gnoseddiabeteswas little changedaftermultivariable adjustment
or age, sex, ethnicity, socioeconomic status, body mass index,
aist circumference, systolic blood pressure, high-density lipopro-
ein cholesterol, triglycerides, antihypertensive and lipid-lowering
edications, smoking, physical activity, and alcohol consumption
Table S3 in Supplement 1). Similarly, the absence of association
etween antidepressant use, study screen-detected diabetes, and
lasma glucose remained unchanged after the adjustment (Table
3 in Supplement 1), as well as in a complete case analysis of
articipants with no missing data at any study phase (Table S4 in
upplement 1).
There was no evidence to suggest that depressive symptoms
xplained the lack of association between antidepressant use and
tudy screen-detected diabetes (odds ratios from amodel adjusted
or depressive symptoms in addition to age, sex, and ethnicity .76,
5%CI: .23–2.46,p .65; and .60, 95%CI: .22–1.65,p .32 at phases
and 9, respectively) because controlling for depressive symptoms
id not increase the magnitude of this association. Depressive
ymptoms were strongly associated with antidepressant use (age-,
ex-, and ethnicity-adjusted odds ratio 6.30, 95% CI: 4.43–9.00, p
0001 at phase 7 and 5.50, 95% CI: 4.02–7.52, p .0001 at phase 9)
nd physician-diagnosed diabetes (odds ratio 1.67, 95% CI: 1.05–
.65, p  .03 at phase 7 and 1.64, 95% CI: 1.20–2.23, p  .002 at
hase 9).
We found support for the notion of reverse causation (i.e., a
ongitudinal association fromphysician-diagnoseddiabetes in rela-
ion to later antidepressant use) in an analysis of 6541 participants
ho reported not taking antidepressant treatment at baseline (for
ntidepressant Use and Diabetes Mellitus by
ds Ratio (95% Confidence Interval)a p Value
Outcome: Incident physician-diagnosed diabetes
1.00
2.34 (1.46, 3.75) .0001
utcome: Incident study screen-detected diabetes
1.00
.88 (.45, 1.72) .70
ted multilevel logistic regression pooling person-
tion equation. Diabetes is considered only at first
ases.
94 had incident physician-diagnosed diabetes ands of A
Od
O
-adjus
stima
nt phample selection, see Figure S1 in Supplement 1). Of them, 5.5%
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982 BIOL PSYCHIATRY 2011;70:978–984 M. Kivima¨ki et al.(n 361) began antidepressant treatment during study follow-up
nd the proportion was higher among participants with physician-
iagnosed diabetes at baseline than in others (age-, sex-, and eth-
icity-adjusted odds ratio 1.72, 95% CI: 1.02–2.88, p .04).
Discussion
In this prospective cohort study of almost 6000 middle-aged
men and women, we found antidepressant use at four clinical ex-
aminations over an 18-year period to be associated with physician-
diagnosed diabetes. However, we observed no association be-
tweenantidepressant use and study screen-detecteddiabetes; that
is, diabetes detected for the first time by routine blood testing as
part of theWhitehall II study. Furthermore, therewasno association
between antidepressant use and glucose levels at any of the four
clinical examinations, and continued antidepressant use was not
associated with progressively increasing levels of fasting or 2-hour
postload glucose over time. These data suggest the observed asso-
ciations between antidepressant therapy and increased risk of dia-
betes are not causal.
Our findings on physician-diagnosed diabetes are in agreement
with the majority of register-based investigations showing a link
between long-term antidepressant use and a clinical record of di-
agnosed diabetes (3–8,27,28). However, as register-based studies
donot capturepeoplewithundiagnoseddiabetes, suchevidence is
potentially affected by detection/ascertainment bias (11). First, the
observed higher proportion of physician-diagnosed diabetes cases
among antidepressant users may relate to the indications for this
drug treatment; that is, diabetes may be detected when ruling out
endocrinologic diseases as a cause of depression (29). Second, an-
Table 4. Longitudinal Association Between Status o
Fasting and 2-Hour Postload Glucose Levels Among
Data Cycles 1 to 3
Combined
Number of
Observationsa
Mea
mm
Antidepressant
Use
No 12,295 .
Yes 285 .
Exposure to
Antidepressant
Use
No 12,197 .
1 examination 300 .
2 examinations 65 .
3 examinations 18 .
Antidepressant
Use
Ou
No 11,123 .
Yes 234 .
Exposure to
Antidepressant
Use
No 11,047 .
1 examination 250 .
2 examinations 50 .
3 examinations 10 .
Data cycle 1 is from phase 3 (1991/1993) to phase
phase 7 (2003/2004); and data cycle 3 from phase 7
CI, confidence interval; Ref, reference group; SD,
a Total number of participants 5487 in analysis of
b From age-, sex-, and ethnicity-adjusted multile
study phases with generalized estimation equation.tidepressant use requires contact with medical care, which may F
www.sobp.org/journalncrease the likelihood of the diagnosis of hidden health problems
uch as diabetes (8). These explanations are consistent with the
bserved differential association with undiagnosed (study screen-
etected) and diagnosed (physician-diagnosed) diabetes and the
ailure to observe a relationship between antidepressant use and
ndiagnosed diabetes. Our findings are also in agreement with
rials on antidepressant medication that do not indicate excess
hort-term risk of type 2 diabetes (30,31).
Unlike clinical record studies, the Diabetes Prevention Program
rial targeted people who were at high risk of diabetes because of
verweight and elevated blood glucose levels (10). In that study,
articipantswere randomly assigned togroups of lifestyle changes,
lucose-lowering medication (metformin), or placebo (10). The au-
hors found that in the lifestyle and placebo groups, participants
onsistently on antidepressants during the study period were
bout twice as likely as nonusers to develop diabetes, although no
uch pattern was seen in the metformin group (10). However, the
tudy did not report stratified analyses for physician-diagnosed
ersus study screen-detected diabetes or comparisons of glucose
rajectories between antidepressant users and nonusers. Further-
ore, despite being based on a clinical trial, the analyses of antide-
ressant use in the Diabetes Prevention Program utilized observa-
ional data because the exposure of interest, antidepressant use,
as not randomized in that study (10). Thus, the observed associa-
ion between antidepressant use and diabetes might have been
ue to unmeasured differences between the two groups of antide-
ressant use rather than a causal effect of antidepressant use.
Several potential confounding factors for the association be-
ween antidepressant use and diabetes have been hypothesized.
idepressant Use and Subsequent Change in
ipants Without Physician-Diagnosed Diabetes
), Mean (95% CI) Difference,
mmol/Lb p Value
come: Subsequent change in fasting glucose
.0 (Ref)
.1 (.0, .1) .11
.0 (Ref)
.1 (.0, .1) .02
.0 (.2, .1) .58
.0 (.3, .3) .81
e: Subsequent change in 2-hour postload glucose
) .0 (Ref)
) .0 (.2, .2) .87
) .0 (Ref)
) .0 (.2, .2) .93
) .2 (.7, .3) .46
) .0 (1.1, 1.1) .98
97/1999); data cycle 2 from phase 5 (1997/1999) to
/2004) to phase 9 (2008/2009).
ard deviation.
g glucose and 4991 in analysis of postload glucose.
inear regression pooling person-observations overf Ant
Partic
n (SD
ol/L
Out
0 (.7)
1 (.7)
0 (.7)
1 (.7)
0 (.6)
0 (.6)
tcom
6 (1.9
5 (1.7
6 (1.9
6 (1.6
3 (1.8
6 (2.4
5 (19
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M. Kivima¨ki et al. BIOL PSYCHIATRY 2011;70:978–984 983depression or a history of chronic or recurrent depression, which
are robust predictors of type 2 diabetes, independent of antide-
pressant therapy (14,29,32). In the present study, antidepressant
users were also more sedentary at baseline and had a higher prev-
alence of smoking as compared with nonusers. In addition, antide-
pressant users were more likely to come from low socioeconomic
groups, a predictor of both depression and diabetes. However,
adjustment for these factors did not change the association be-
tween antidepressant use and physician-diagnosed diabetes. Our
study, in combination with the evidence that physician-diagnosed
diabetes also predicts future antidepressant use (33), is consistent
with a view that being treated for one condition increases the
likelihoodofbeingdiagnosedwith theother condition, irrespective
of other characteristics of the patient.
Confounding factors may inflate, but could also suppress, the
magnitude of an unadjusted association, contributing to false null
findings. In the present study, antidepressant use was unrelated to
screen-detected diabetes and plasma glucose both before and af-
ter adjustments for potential confounding factors, suggesting that
the absence of associations with undiagnosed diabetes and glu-
cose is not an artifact resulting from a suppression effect of the
confounders.
It is important to consider potential limitations to the present
study that could contribute to false-negative findings. First, the
participants of the Whitehall II study are from an occupational co-
hort that is likely to cover a more restricted range of health status
compared with the general population. However, a large bias due
to restricted variance seems unlikely because themagnitude of the
association between antidepressant use and diagnosed diabetes
was comparable with that observed in other cohorts (3–10). Sec-
ond, despite a high response to the successive data collection
phases, loss to follow-up accumulated over the extended time pe-
riod, as is inevitable in all long-term prospective studies. However,
differences between the included participants and the total base-
line population were generally small. Third, despite the large sam-
ple size, the number of diabetes cases among antidepressant users
was relatively small; thus, the findings should be interpreted with
caution.We did not have precise information on prescriptions (e.g.,
dosage) and the sample size was not large enough for analyses of
specific classes of antidepressants. Given that side effects may vary
dependingonadrug’s chemical substance, antidepressant-specific
analyses should be undertaken in future studies (34). Fourth, error
in the measurement of glucose and diabetes status is a potential
source of false-negative findings. This seems, however, an unlikely
explanation of our findings because we used the World Health
Organization diabetes definition, based on standard oral glucose
tolerance testing, considered to be a gold standard measure (26).
Indeed, few previous studies have data based on glucose test avail-
able across repeated examinations. Fifth, we identified persons
with depressive symptoms using a standard, validated question-
naire measure: the Center for Epidemiologic Studies Depression
Scale (21,22). This instrument has been shown to be a sensitive
measure of mental health problems in the general population and
in diabetic patients but was not designed to make a psychiatric
diagnosis of first or recurrent major depression. Thus, we cannot
exclude the possibility of confounding by unmeasured depression.
However, as depression is known to underlie antidepressant use
and increased risk of diabetes, unadjusted associations between
antidepressant use and diabetes will represent, if anything, overes-
timates rather than underestimates of the true association. It there-
fore seems unlikely that unmeasured depression removed the as-
sociationsof antidepressant usewith screen-detecteddiabetes andlycemia in our study, as indication bias by depression should have
nflated these associations.
onclusion
We have demonstrated that detection/ascertainment bias may
ave compromised evidence in this field of research. Our longitudi-
al study of British men and women suggests that the adverse
ffect of antidepressant use on type 2 diabetes risk is biologically
mplausible andmight have been overestimated in previous epide-
iologic studies. This evidence suggests that concerns about im-
ortant diabetogenic side effects of antidepressants might have
een unfounded.
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